Impact of Age and Comorbidity on Non–Small-Cell Lung Cancer Treatment in Older Veterans
Authors:
- 1 May 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (13) , 1447-1455
Abstract
Purpose: Because comorbidity affects cancer treatment outcomes, guidelines recommend considering comorbidity when making treatment decisions in older patients with lung cancer. Yet, it is unclear whether treatment is targeted to healthier older adults who might reasonably benefit. Patients and Methods: Receipt of first-line guideline-recommended treatment was assessed for 20,511 veterans age ≥ 65 years with non–small-cell lung cancer (NSCLC) in the Veterans Affairs (VA) Central Cancer Registry from 2003 to 2008. Patients were stratified by age (65 to 74, 75 to 84, ≥ 85 years), Charlson comorbidity index score (0, 1 to 3, ≥ 4), and American Joint Committee on Cancer stage (I to II, IIIA to IIIB, IIIB with malignant effusion to IV). Comorbidity and patient characteristics were obtained from VA claims and registry data. Multivariate analysis identified predictors of receipt of guideline-recommended treatment. Results: In all, 51% of patients with local, 35% with regional, and 27% with metastatic disease received guideline-recommended treatment. Treatment rates decreased more with advancing age than with worsening comorbidity for all stages, such that older patients with no comorbidity had lower rates than younger patients with severe comorbidity. For example, 50% of patients with local disease age 75 to 84 years with no comorbidity received surgery compared with 57% of patients age 65 to 74 years with severe comorbidity (P < .001). In multivariate analysis, age and histology remained strong negative predictors of treatment for all stages, whereas comorbidity and nonclinical factors had a minor effect. Conclusion: Advancing age is a much stronger negative predictor of treatment receipt among older veterans with NSCLC than comorbidity. Individualized decisions that go beyond age and include comorbidity are needed to better target NSCLC treatments to older patients who may reasonably benefit.Keywords
This publication has 48 references indexed in Scilit:
- Surgical treatment of non-small cell lung cancer in octogenariansInteractive CardioVascular and Thoracic Surgery, 2011
- Pathological Diagnosis and Classification of Lung Cancer in Small Biopsies and Cytology: Strategic Management of Tissue for Molecular TestingSeminars in Respiratory and Critical Care Medicine, 2011
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing NationJournal of Clinical Oncology, 2009
- Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10Journal of Clinical Oncology, 2007
- Complications and outcomes after pulmonary resection for cancer in patients 80 to 89 years of ageEuropean Journal of Cardio-Thoracic Surgery, 2005
- Similar Long-term Survival of Elderly Patients With Non-small Cell Lung Cancer Treated With Lobectomy or Wedge Resection Within the Surveillance, Epidemiology, and End Results DatabaseChest, 2005
- Surgical Resection for Lung Cancer in the OctogenarianChest, 2004
- The Outcome of Combined-Modality Therapy for Stage III Non–Small-Cell Lung Cancer in the ElderlyJournal of Clinical Oncology, 2003
- Therapy choices among older patients with lung carcinomaCancer, 2001